U.S. Immigration Fund Welcomes Emily Zhu as Vice President of Business Development, Head of East Asia
PALM BEACH, Fla., April 30, 2025 /PRNewswire/ -- U.S. Immigration Fund (USIF), a leading EB-5 Regional Center operator, is pleased to announce the addition of Emily Zhu as Vice President of Business Development, Head of East Asia. In her role, Zhu will focus on expanding USIF's presence in East Asia, fostering relationships with investors, and guiding them through the EB-5 process. She will also work to educate individuals currently in the U.S. on non-immigrant visas about their options within EB-5.
With nearly a decade of experience in the EB-5 industry, Zhu brings extensive expertise in capital raising, investor relations, and strategic business development. Originally from China and residing in the U.S. since 2009, she began her EB-5 career in 2015 at a boutique immigration law firm and regional center in New York. From 2016 to 2019, she served as an in-house representative for a New York-based developer and regional center, managing investor relations and capital raising efforts.
'USIF has long been recognized as an industry leader in the EB-5 space, and I am thrilled to join this exceptional team,' said Zhu. 'Our priority is to connect international investors with financially sound real estate projects that create jobs and support families in securing U.S. residency. I look forward to helping investors navigate the EB-5 process with transparency and expert guidance.'
'We are proud to welcome Emily Zhu as Vice President of Business Development, Head of East Asia. Emily's deep understanding of the East Asian market and her commitment to investor success will be instrumental in expanding our reach and delivering premier EB-5 solutions,' explains Nicholas Mastroianni III, President & Chief Marketing Officer of U.S. Immigration Fund. 'Her leadership will help us connect with more families and entrepreneurs who are looking to build a future in the U.S. through the EB-5 program.'
Since 2010, USIF has assisted over 5,000+ EB-5 applicants worldwide, facilitating investments in major development projects and successfully securing billions in funding. In October 2024, USIF's Summit NJ Project received I-956F approval from USCIS, underscoring the company's commitment to compliance and excellence in the EB-5 industry.
For more information or to schedule a consultation with Emily Zhu, use the links below.
Book a Consultation with Emily
Visit our website
Photo: https://mma.prnewswire.com/media/2676866/Emily_Zhu.jpg
Logo: https://mma.prnewswire.com/media/2586832/5294746/US_Immigration_Fund_Logo.jpg
View original content to download multimedia: https://www.prnewswire.com/news-releases/us-immigration-fund-welcomes-emily-zhu-as-vice-president-of-business-development-head-of-east-asia-302442590.html
SOURCE U.S. Immigration Fund
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
CNOOC Limited Brings On-stream Weizhou 5-3 Oilfield Development Project
HONG KONG, June 8, 2025 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) today announces that Weizhou 5-3 Oilfield Development Project has commenced production. The project is located in the Beibu Gulf Basin of the South China Sea, with an average water depth of approximately 35 meters. The main production facility includes 1 self-installing wellhead platform, which leverages the adjacent existing facilities for development. 10 development wells are planned to be commissioned, including 7 production wells, 2 water injection wells and 1 gas injection well. The project is expected to achieve a plateau production of approximately 10,000 barrels of oil equivalent per day in 2026. The oil property is medium crude. CNOOC Limited holds 51% interest in the project, and Smart Oil Investment Ltd. holds the remaining 49%. — End — Notes to Editors: More information about the Company is available at *** *** *** *** This press release includes forward looking information, including statements regarding the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial results. The words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company as of this date in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company's expectations, including but not limited to those associated with macro-political and economic factors, fluctuations in crude oil and natural gas prices, the highly competitive nature of the oil and natural gas industry, climate change and environmental policies, the Company's price forecast, mergers, acquisitions and divestments activities, HSSE and insurance policies and changes in anti-corruption, anti-fraud, anti-money laundering and corporate governance laws and regulations. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements. The Company cannot assure that the results or developments anticipated will be realised or, even if substantially realised, that they will have the expected effect on the Company, its business or operations. *** *** *** *** For further enquiries, please contact: Ms. Cui LiuMedia & Public RelationsCNOOC LimitedTel: +86-10-8452-6641Fax: +86-10-8452-1441E-mail: mr@ Mr. Cheng YaoEver Bloom (HK) Communications Consultants Group LimitedTel：+852 5540 0725Fax：+852 2111 1103Email： View original content to download multimedia: SOURCE CNOOC Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
an hour ago
- Yahoo
Graham Corporation To Participate in Upcoming Investor Conferences
BATAVIA, N.Y., June 05, 2025--(BUSINESS WIRE)--Graham Corporation (NYSE: GHM) ("GHM" or the "Company"), a global leader in the design and manufacture of mission critical fluid, power, heat transfer and vacuum technologies for the defense, space, energy, and process industries, today announced that Matthew J. Malone, President and Chief Executive Officer, Christopher J. Thome, Vice President - Finance and CFO, will participate at the following upcoming investor conferences: Wells Fargo 2025 Industrials ConferenceDate: Thursday, June 12, 2025Location: Chicago, ILPresentation Time: 1:45 pm ETLive Webcast Link: Here Northland Growth ConferenceDate: Wednesday, June 25, 2025Location: VirtualPresentation Time: 1x1 Meetings Only Interested investors should contact their sales representative to register and schedule one-on-one or group meetings. A live webcast of the presentation, along with presentation materials, will be available at the Events & Presentation section of the Company's investor relations website at About Graham CorporationGraham is a global leader in the design and manufacture of mission critical fluid, power, heat transfer and vacuum technologies for the defense, space, energy, and process industries. Graham Corporation and its family of global brands are built upon world-renowned engineering expertise in vacuum and heat transfer, cryogenic pumps, and turbomachinery technologies, as well as its responsive and flexible service and the unsurpassed quality customers have come to expect from the Company's products and systems. Graham Corporation routinely posts news and other important information on its website, where additional information on Graham Corporation and its businesses can be found. View source version on Contacts For more information, contact: Christopher J. ThomeVice President - Finance and CFOPhone: (585) 343-2216 Tom CookInvestor Relations(203) Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
